论文部分内容阅读
目的:观察血必净注射液对晚期实体瘤相关类白血病反应的临床疗效。方法:将符合纳入标准的晚期实体瘤相关类白血病反应患者60例随机分为治疗组32例和对照组28例,在常规抗感染、对症支持治疗的基础上,治疗组加用血必净注射液50m L静脉滴注,每天2次,连续治疗14天。2组患者治疗前、治疗7天后、治疗14天后分别采血检测白细胞计数(WBC)、C-反应蛋白(CRP)、降钙素原(PCT)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)、血浆凝血酶原时间(PT)和活化部分凝血酶原时间(APTT),并记录观察期间的死亡率。结果:与治疗前比较,治疗14天后治疗组WBC、CRP、PCT、TNF-α、IL-6、PT和APTT均下降,差异均有统计学意义(P<0.05);治疗14天后,治疗组WBC、CRP、PCT、TNF-α、IL-6及APTT与对照组比较,差异均有统计学意义(P<0.05)。观察期内治疗组死亡率低于对照组,差异有统计学意义(P<0.05)。结论:血必净注射液可有效降低晚期实体瘤相关类白血病反应患者外周血中相关炎性介质的表达,减轻全身炎症反应,降低出血风险,改善预后。
Objective: To observe the clinical effect of Xuebijing injection on advanced solid tumor related leukemia. Methods: Sixty patients with advanced solid tumor-associated leukemia who met the inclusion criteria were randomly divided into treatment group (n = 32) and control group (n = 28). On the basis of conventional anti-infective and symptomatic supportive therapy, Liquid 50m L intravenous infusion, 2 times a day for 14 days. Two groups of patients before treatment, after treatment for 7 days, 14 days after treatment, respectively, blood leucocyte count (WBC), C-reactive protein (CRP), procalcitonin (PCT), tumor necrosis factor- (IL-6), plasma prothrombin time (PT), and activated partial prothrombin time (APTT), and the mortality during the observation period was recorded. Results: After treatment for 14 days, the WBC, CRP, PCT, TNF-α, IL-6, PT and APTT in the treatment group were significantly lower than those before treatment (all P <0.05) The differences of WBC, CRP, PCT, TNF-α, IL-6 and APTT between the two groups were statistically significant (P <0.05). During the observation period, the mortality of the treatment group was lower than that of the control group, with significant difference (P <0.05). Conclusion: Xuebijing injection can effectively reduce the expression of related inflammatory mediators in peripheral blood of patients with advanced solid tumor related leukemia, reduce the systemic inflammatory response, reduce the risk of hemorrhage and improve the prognosis.